# Eribulin and Lenvatinib in Advanced Solid Tumors

> **NCT02640508** · PHASE2 · COMPLETED · sponsor: **Virginia G. Kaklamani** · enrollment: 29 (actual)

## Conditions studied

- Cancer
- Solid Tumor

## Interventions

- **DRUG:** Eribulin
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT02640508
- **Lead sponsor:** Virginia G. Kaklamani
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05
- **Primary completion:** 2020-11-24
- **Final completion:** 2023-01-12
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2024-05-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02640508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02640508, "Eribulin and Lenvatinib in Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02640508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*